Safey and Efficacy of the Intracoronary administration of Allogeneic human Cardiac Stem Cells in Patients with Ischemic Chronic Heart Failure at High Risk for Sudden Cardiac Death (CaSeC-HF)

Resumen del proyecto

Heart failure (HF) has become a large-scale health problem. Indeed, HF is responsible for up to 5% of hospitalizations in > 65 years old patients in western societies. Sudden cardiac death remains is one of the major sources of mortality in HF patients, particularly in patients with chronic ischemic heart disease (IHD). Despite widespread usage of implantable cardiac defibrillators (ICDs), a large proportion of patients with HF still die of SCD. Patients at highest risk are those with a previous episode of ventricular tachycardia or fibrillation (VT/VF). In fact, despite ablation therapies and anti-arrhythmic drugs, 30 to 50% of patients with HF and a previous treated episode of VT/VF will recur during follow-up. Any strategy focused on avoiding the recurrence of ventricular arrhythmia may have an important impact on long-term outcomes of patients with HF and IHD. Importantly, meta-analyses and recent clinical trials have demonstrated that clinical benefit of cardiac regenerative therapy in chronic LV dysfunction is due to its impact reducing the risk of SCD. Allogeneic CSCs have proven to be a safe regenerative therapy for the heart which can be readily distributed and administrated. CaSeC-HF is designed as a phase Ib/IIa multicentric, randomized, double-blind, placebo-controlled clinical trial aimed to evaluate the safety and efficacy of intracoronary administration of allogeneic cardiac stem cells (CSC) in patients with chronic HF at very high risk of SCD. The rationale is based on pre-clinical evidence demonstrating an improvement of myocardial electrophysiological properties in a pig model of chronic IHD. A total of 54 patients with HF, IHD, at high risk of SCD ?previous episode of VT/VF and positive inducibility using non-invasive ICD stimulation after therapeutic management? shall be randomized (2:1) to receive a 3-vessel intracoronary administration of either allogeneic-CSCs or placebo. The investigational product will be manufactured centrally in a GMP

Palabras clave

insuficiencia cardíaca
célula madre cardíaca
alogénico
alogénica
muerte súbita
ensayo clínico
taquicardia ventricular

Convocatoria

Acción Estratégica en Salud (AES)

Periodo de ejecución

01/01/2019 - 31/12/2022

Investigador Principal

FERNANDEZ-AVILES DIAZ, FRANCISCO

Centro beneficiario

FUNDACION INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON

Centro de realización

INSTITUTO DE INVESTIGACION SANITARIA GREGORIO MARAÑON (IISGM)

Comunidad Autónoma

Comunidad de Madrid

Provincia

Madrid

Financiación

339,625 €